INM

+ Watchlist + Portfolio

InMed Pharmaceuticals Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.35
52-Week Range: $0.58 – $2.50
Market Cap: $7.31M
P/E (TTM): —
EPS (TTM): -2.84
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.62
PEG Ratio: —
Return on Equity: -156.77%
Return on Assets: -66.46%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.37
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-3.19M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.07M

INM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$1.09M	$4.14M	$4.60M	$0.00	$0.00
Cost of Revenue	$545.89K	$2.73M	$3.50M	$3.24M	—
Gross Profit	$543.55K	$1.40M	$1.10M	$1.71M	—
Research & Development	$7.28M	$3.73M	$3.22M	$2.82M	$3.03M
Selling, General & Admin	$6.87M	$5.85M	$5.80M	$5.41M	$6.66M
Operating Expenses	—	$9.78M	$9.24M	$8.45M	$9.90M
Operating Income	-$13.79M	-$8.38M	-$8.13M	-$8.45M	-$9.90M
EBITDA	-$13.28M	-$7.78M	-$7.06M	-$7.78M	-$10.65M
Pretax Income	-$18.60M	-$7.93M	-$7.67M	-$8.69M	-$11.37M
Income Tax	$0.00	$13.10K	$7.10K	$0.00	$0.00
Net Income	-$18.60M	-$7.95M	-$7.68M	-$8.16M	-$12.56M
Diluted EPS	-663.40	-65.00	-20.20	-8.36	-3.12
Diluted Shares	28041	122422	381053	975895	4.16M

INM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$6.18M	$8.91M	$6.57M	$10.74M	$2.19M
Receivables	$88.03K	$260.40K	$352.84K	$465.10K	—
Inventory	$2.49M	$1.62M	$1.24M	$961.17K	—
Current Assets	$9.60M	$11.33M	$8.69M	$12.87M	$2.68M
Total Assets	$12.79M	$14.11M	$11.82M	$15.58M	$3.03M
Current Liabilities	$3.32M	$2.00M	$1.97M	$1.84M	$1.96M
Total Debt	$793.77K	$391.71K	$962.66K	$741.26K	$0.00
Total Liabilities	$3.71M	$2.02M	$2.62M	$2.15M	$1.96M
Retained Earnings	-$93.45M	-$101.40M	-$109.08M	-$117.24M	-$130.23M
Shareholders' Equity	$9.08M	$12.09M	$9.21M	$13.43M	$1.08M
Working Capital	$6.28M	$9.33M	$6.72M	$11.03M	$721.65K

INM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$15.58M	-$7.28M	-$6.99M	-$8.10M	-$8.64M
Capital Expenditure	-$39.11K	-$161.80K	-$9.29K	—	—
Free Cash Flow	-$15.62M	-$7.45M	-$7.00M	-$8.10M	-$8.64M
Depreciation & Amortisation	$511.79K	$596.00K	$604.52K	$534.72K	$708.36K
Stock-Based Compensation	$697.89K	$278.15K	$137.71K	$119.31K	$106.87K
Investing Cash Flow	-$673.00K	-$661.80K	-$9.29K	$0.00	$0.00
Financing Cash Flow	$15.07M	$10.68M	$4.65M	$12.27M	$94.50K
Net Change in Cash	-$1.19M	$2.74M	-$2.34M	$4.17M	-$8.55M

INM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$1.30M	$1.12M	$820.19K	$0.00	$0.00
Cost of Revenue	$1.09M	$728.06K	$716.96K	$635.99K	—	—
Gross Profit	$175.63K	$576.65K	$403.16K	$184.19K	—	—
Research & Development	$425.37K	$112.72K	$581.61K	$630.64K	$1.02M	$805.74K
Selling, General & Admin	$1.58M	$2.25M	$1.53M	$1.62M	$1.74M	$2.36M
Operating Expenses	$2.06M	$2.42M	$2.17M	$2.30M	$2.82M	$3.21M
Operating Income	-$2.06M	-$1.84M	-$1.76M	-$2.12M	-$2.82M	-$3.21M
EBITDA	-$1.94M	-$1.64M	-$1.61M	-$1.87M	-$2.66M	-$4.57M
Pretax Income	-$2.07M	-$1.79M	-$1.73M	-$2.03M	-$2.79M	-$4.84M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$2.12M	-$1.79M	-$1.73M	-$2.03M	-$2.97M	-$5.84M
Diluted EPS	-1.94	—	-0.44	-0.51	-0.73	—
Diluted Shares	1.10M	—	3.95M	3.95M	4.05M	—

INM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$4.68M	$10.74M	$9.33M	$6.95M	$5.16M	$2.19M
Receivables	$367.81K	$465.10K	$343.47K	$182.97K	—	—
Inventory	$813.97K	$961.17K	$890.81K	$947.90K	—	—
Current Assets	$6.41M	$12.87M	$10.80M	$8.79M	$6.89M	$2.68M
Total Assets	$9.28M	$15.58M	$13.36M	$11.19M	$9.13M	$3.03M
Current Liabilities	$1.84M	$1.84M	$1.55M	$1.48M	$2.21M	$1.96M
Total Debt	$848.59K	$741.26K	$640.24K	$531.95K	$420.15K	$0.00
Total Liabilities	$2.26M	$2.15M	$1.77M	$1.60M	$2.24M	$1.96M
Retained Earnings	-$115.45M	-$117.24M	-$118.96M	-$120.99M	-$123.96M	-$130.23M
Shareholders' Equity	$7.02M	$13.43M	$11.59M	$9.59M	$6.89M	$1.08M
Working Capital	$4.57M	$11.03M	$9.24M	$7.31M	$4.68M	$721.65K

INM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.66M	-$1.78M	-$1.61M	-$2.38M	-$1.70M	-$2.96M
Free Cash Flow	-$1.66M	-$1.78M	-$1.61M	-$2.38M	-$1.70M	-$2.96M
Depreciation & Amortisation	$129.58K	$131.08K	$156.68K	$158.02K	$133.46K	$260.20K
Stock-Based Compensation	$40.45K	$26.73K	$20.20K	$25.26K	$38.77K	$22.63K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$2.92M	$8.17M	-$137.18K	$0.00	$231.68K	-$1.00
Net Change in Cash	$1.26M	$6.40M	-$1.74M	-$2.38M	-$1.46M	-$2.96M

Market Snapshot

About

InMed Pharmaceuticals Inc. is a pharmaceutical company developing novel therapies through the research and development of cannabinoid-based medications. The company focuses on diseases with high unmet medical needs, including epidermolysis bullosa, a rare genetic skin disorder, and glaucoma. InMed has developed proprietary biosynthesis technology to manufacture pharmaceutical-grade cannabinoids at commercial scale, reducing reliance on traditional plant-based extraction. The company's pipeline includes both topical and ocular drug candidates targeting specific medical conditions where cannabinoids may provide therapeutic benefits.